Department of Hematology, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Leuk Lymphoma. 2012 Jul;53(7):1282-8. doi: 10.3109/10428194.2011.654115. Epub 2012 Feb 13.
Alterations in the function of the p53 pathway are frequently described in chronic lymphocytic leukemia (CLL), mostly associated with deletion of 17p13 and/or mutations of the TP53 gene. In the present study, we investigated 103 CLLs for the impact of protein expression of full-length p53 and its isoforms β and γ. A strong correlation between deletions of 17p13 and an accumulation of full-length p53 protein was found and was associated with a worse outcome compared to CLL with normal p53 (treatment-free survival p < 0.001, overall survival p = 0.04). Interestingly, the relative expression levels between full-length p53 protein and its isoforms β and γ were significantly altered in CLL even without deletions of 17p13, compared to normal B-cells (p = 0.005). Furthermore, CLLs with higher p53 protein ratios showed worse clinical courses compared to CLLs with lower p53 protein ratios. Taken together, the differential expression of p53 isoforms could disrupt the p53 response and contribute to CLL pathogenesis.
p53 通路功能的改变在慢性淋巴细胞白血病(CLL)中经常被描述,主要与 17p13 的缺失和/或 TP53 基因突变有关。在本研究中,我们研究了 103 例 CLL,以研究全长 p53 及其异构体β和γ的蛋白表达的影响。发现 17p13 缺失与全长 p53 蛋白的积累之间存在很强的相关性,与正常 p53 的 CLL 相比,其预后更差(无治疗生存 p<0.001,总生存 p=0.04)。有趣的是,与正常 B 细胞相比,即使没有 17p13 的缺失,CLL 中全长 p53 蛋白与其异构体β和γ之间的相对表达水平也显著改变(p=0.005)。此外,与 p53 蛋白比值较低的 CLL 相比,p53 蛋白比值较高的 CLL 表现出更差的临床病程。总之,p53 异构体的差异表达可能破坏 p53 反应,并有助于 CLL 的发病机制。